On February 26, 2025, Latham’s Healthcare & Life Sciences Industry Group discussed the regulatory and legislative considerations under the new Trump administration.
As the healthcare and life sciences industry faces a dynamic landscape, Latham provides valuable insights into the anticipated changes and challenges, with particular focus on key rulemakings and policy pronouncements.
This webcast delves into:
Antitrust
- How the Trump administration has shifted antitrust enforcement priorities and how to navigate the evolving landscape
- What to expect from new agency leadership at both the FTC and DOJ Antitrust Division
- Key considerations when planning your next transformative acquisition
FDA
- Agency leadership appointments and the potential impact on regulatory priorities and policy direction
- How the Trump administration may shift its enforcement priorities, including to incentivize the nearshoring of manufacturing operations
Government Investigations and SEC Enforcement
- Expected changes in enforcement priorities, including as they relate to the False Claims Act
- The SEC’s expected enforcement priorities, including an anticipated focus on more traditional enforcement areas and individual accountability